[email protected]

– USA, PA – Egalet Corporation (Nasdaq:EGLT), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that Jean-Francois Formela, MD has resigned from Egalet’s board of directors. Andrea Heslin Smiley, chief executive officer of VMS BioMarketing, will take Dr. Formela’s board seat and Elaine Hochberg, former chief commercial officer for Forest Laboratories, has been added to the board.

Dr. Formela has served on the board of directors since 2010 and was chairman of the board from 2012 to 2015.

“We’re thankful to Jean-Francois for his exceptional dedication and service to Egalet as we grew from a development stage company to a commercial business,” said Bob Radie, Egalet’s president and chief executive officer. “Now with three marketed products, Elaine’s commercial expertise and Andrea’s entrepreneurial spirit and business acumen should greatly benefit us as we focus on commercial execution and moving toward sustainability.”

Ms. Smiley has served as president and chief executive officer of VMS BioMarketing since 2011. Ms. Smiley spent 18 years in the pharmaceutical industry leading multiple business units in the development and execution of biotech, device, and pharmaceutical product strategies to drive brand equity, increase market share, and improve patient adherence. Her diverse biotech and pharmaceutical experiences span a wide range of disease areas and functional roles including launching multiple biotech and pharmaceutical drugs and devices. Ms. Smiley has served on the board of numerous organizations including the Indiana Alzheimer’s Association, Indiana Salvation Army, and the Lung Force Women’s Cabinet, and she received a gubernatorial appointment to the Indiana Commission for Women. She earned her BA in economics from DePauw University where she was an Honors Management Fellow.

Ms. Hochberg has more than 30 years of leadership experience. Currently she is a managing partner of Elaran LLC, a business strategy and management firm. Previously, Ms. Hochberg worked for Forest Laboratories where, over 17 years, she rose through several positions to become the company’s first chief commercial officer. At Forest, Ms. Hochberg was responsible for the US sales and marketing organization and drove the commercial strategy and implementation for the company’s full range of products in multiple therapeutic areas, including specialty products. She also headed Forest’s International Business which included both prescription and over-the-counter (OTC) brands. During her tenure, Ms. Hochberg helped transform Forest into a major mid-cap branded pharmaceutical company which lead to the company’s acquisition by Actavis for $24 billion. Prior to Forest, she was at Wyeth-Ayerst Laboratories and held product and marketing leadership roles in the pediatric and vaccines divisions. She serves on the board of Akcea Therapeutics and on several non-profit boards in New York City. Ms. Hochberg earned her BA and MBA from Columbia University.

About Egalet

Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO™ ER (morphine sulfate) extended-release tablets for oral use only –CII, developed using Egalet’s proprietary Guardian™ Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. Using Guardian Technology Egalet is developing a pipeline of clinical-stage, product candidates including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles.

For more information : http://www.egalet.com

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

Talent4Boards Team

here the original post =>

Comments are closed.